Thymosin Alpha-1 9mg
T-cell and dendritic activator — immune resilience against chronic infection
BioBlend Pharma Grade3ml vialImmune Modulator
Thymosin Alpha-1 9mg
T-cell and dendritic activator — immune resilience against chronic infection
Contact for pricing
Administration
Injectable
First Results
2–4 weeks
Cycle Length
8–16 weeks
Clinical Uses
- Chronic viral infections
- Low immune resilience
- Adjunct in autoimmune balance
- Post-illness recovery
Key Benefits
- Increases T-cell maturation and activity
- Enhances dendritic cell function
- Modulates rather than overstimulates
- Supports clearance of persistent infection
How It Works — Mechanism of Action
Thymosin Alpha-1 promotes T-cell differentiation, modulates Toll-like receptors and supports dendritic cell signalling — restoring coordinated immunity without inflammatory excess.
Your Thymosin Alpha-1 9mg protocol, wherever you are
A pre-filled, easy-to-carry pen for self-administration at home, the gym or the office. Dispensed safely after physician approval and delivered cold-chain to you.
Dosage Protocol
1.5 mg subcutaneous injection 2x weekly, or per prescriber. Cycle 8–16 weeks.
When to Expect Results
Weeks 2–4: improved energy. Weeks 8–12: measurable immune panel improvement.
Side Effects
Generally well tolerated. Rare: mild injection-site redness. Contact your physician for any unusual symptom.
Contraindications
Active cancer, pregnancy, hypersensitivity to peptide components. Always review with your physician.
Best Stacked With
Consult your physician for synergistic stacking options matched to your goal.
Understanding Your Body’s Language
Ready to start your Thymosin Alpha-1 9mg protocol?
All peptide protocols require a physician consultation and blood work. Our licensed UAE team will craft a personalised plan for you.
Book a consultation